Zacks Investment Research upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a research report report published on Wednesday, Zacks.com reports. They currently have $9.25 price objective on the stock.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Other analysts have also recently issued reports about the stock. Robert W. Baird reaffirmed an outperform rating and set a $25.00 price objective (up from $15.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. ValuEngine raised shares of Vistra Energy from a hold rating to a buy rating in a research note on Wednesday, July 3rd. HC Wainwright reaffirmed a buy rating and set a $48.00 price objective (down from $52.00) on shares of CELYAD SA/ADR in a research note on Friday, July 5th. Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the stock a hold rating in a research note on Monday, July 8th. Finally, BidaskClub raised shares of Zumiez from a sell rating to a hold rating in a research note on Saturday, June 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The company has a consensus rating of Hold and an average target price of $17.41.
NASDAQ KPTI opened at $8.03 on Wednesday. The company has a 50-day simple moving average of $6.37. Karyopharm Therapeutics has a twelve month low of $3.92 and a twelve month high of $21.71. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.75 million. Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. As a group, research analysts anticipate that Karyopharm Therapeutics will post -3.79 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the business. Legal & General Group Plc grew its stake in shares of Karyopharm Therapeutics by 31.3% during the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock valued at $95,000 after purchasing an additional 2,411 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Karyopharm Therapeutics by 660.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after purchasing an additional 3,300 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Karyopharm Therapeutics by 20.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock valued at $419,000 after purchasing an additional 3,400 shares during the last quarter. Weiss Multi Strategy Advisers LLC grew its stake in shares of Karyopharm Therapeutics by 24.4% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 25,000 shares of the company’s stock valued at $234,000 after purchasing an additional 4,905 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Karyopharm Therapeutics by 169,300.0% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after purchasing an additional 10,158 shares during the last quarter. 84.20% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Featured Article: The Role of a Fiduciary and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.